Aspire-Lakewood (ASBP) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed Radiopharm Theranostics (RADX) over the past year, gaining 83.8% versus a loss of 86.1%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $9.9 million), about 1.0 times the size. Radiopharm Theranostics converts more of its revenue into profit, with a net margin of -1055.3% versus -394725.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | RADX |
|---|---|---|
| Share price | $7.13 | $0.6304 |
| Market cap | $10.00M | $9.90M |
| 1-day change | -5.44% | -9.71% |
| YTD return | +35.04% | -87.92% |
| 1-year return | +83.76% | -86.15% |
| EPS (TTM) | $-30.89 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.20K | $3.63M |
| Revenue growth (YoY) | — | +1114.27% |
| Net income (latest FY) | $-24.48M | $-38.34M |
| Gross margin | -1.87% | 1.08% |
| Operating margin | -312016.95% | -1050.63% |
| Net margin | -394725.06% | -1055.27% |
| 52-week high | $9.50 | $16.25 |
| 52-week low | $0.11 | $0.63 |
| Distance from 52-week high | -24.95% | -96.12% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +2595.11% |
| Average volume | 29.24K | 55.23K |
| Shares outstanding | 1.40M | 15.70M |
| Employees | — | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed RADX by 169.9 percentage points over the past year.
- Radiopharm Theranostics is more profitable, keeping -1055.3 cents of every revenue dollar as net income versus -394725.1 cents for Aspire-Lakewood.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
ASBP vs RADX FAQ
Which is bigger, Aspire-Lakewood or Radiopharm Theranostics?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $9.90M for Radiopharm Theranostics (RADX).
Which stock has performed better over the past year, ASBP or RADX?
ASBP returned +83.76% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.